Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

Fig. 1

Design of NK cell-reprogramming piggyBac vector, CAR construct, and non-viral delivery platform. a Diagram describing the fabrication of the PBAE/DNA vector complex and structure of piggyBac CAR construct. Herein, two plasmids comprising the piggyBac transposon/transposase system encoding an NKG2D.CAR and the hyperactive iPB7 transposase, respectively, were complexed with the PBAE 447 polymer. The transposon/iPB7 transposase comprises the following genetic elements: CAG, CMV early enhancer fused to modified chicken β-actin promoter; SV40 pA, Simian virus 40 late polyadenylation signal; CMV, human cytomegalovirus immediate early enhancer/promoter; mCherry, variant of mRFP1 generated by mutagenesis; EF1A, eukaryotic translation elongation factor 1 alpha 1; Kozak, kozak consensus sequence; BGH PA, bovine growth hormone polyadenylation signal; rBG pA, rabbit β-globin polyadenylation signal; AMP, ampicillin resistance gene; ORI, origin of replication. b Chemical structure of the PBAE 447 polymer. c Schematic of the NKG2D.CAR construct containing NKG2D as the ectodomain linked to DAP10 and CD3ζ as key signaling molecules

Back to article page